• People
  • Practices
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Search
  • Biography
  • Education
  • Recent Publications
Profile Picture

Melanie E. Neary

Melanie
Neary

Associate Attorney

CONTACT INFO

mneary@gibsondunn.com

TEL:+1 415.393.8243

FAX:+1 415.374.8448

San Francisco

555 Mission Street, Suite 3000, San Francisco, CA 94105-0921 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

Capital Markets Emerging Companies Fashion, Retail and Consumer Products Life Sciences Media, Entertainment and Technology Mergers and Acquisitions Securities Regulation and Corporate Governance

BIOGRAPHY

Melanie Neary is a senior associate in the San Francisco office of Gibson, Dunn & Crutcher , where she practices in the firm’s Corporate Transactions Practice Group, with a practice focused on advising clients in connection with a variety of financing transactions, including initial public offerings, secondary equity offerings and venture and growth equity financings as well as complex corporate transactions, including mergers and acquisitions. Melanie also regularly advises clients on corporate law matters, Securities and Exchange Commission reporting requirements and ownership filings and corporate governance.

Selected Experience

  • Initial Public Offerings: Apogee Therapeutics, Rain Oncology, Shattuck Labs, Biora Therapeutics, 89bio, Cricut, StepStone Group, Petco Health and Wellness Company, Odonate Therapeutics, Excelerate Energy
  • Follow-on Equity Offerings: Biora Therapeutics, Viridian Therapeutics, Protagonist Therapeutics, Ultragenyx Pharmaceutical, 89bio, Odonate Therapeutics, Rain Oncology, Rockwell Medical, Heron Therapeutics, Rocket Pharmaceuticals, StepStone Group, Leslie’s, Peloton, Eledon Pharmaceuticals
  • ATM Facilities: Protagonist Therapeutics, Shattuck Labs, Rain Oncology, Biora Therapeutics, Ultragenyx, Viridian Therapeutics, 89bio, Rockwell Medical, California Water Service Group, Urovant
  • Debt Offerings: Mauser Packaging, California Water Service Group, Wells Fargo & Company and Wells Fargo Bank, N.A., Gran Tierra Energy, Keysight Technologies, Magnite
  • Venture Financings: Apogee Therapeutics – Series B, Cullgen – Series C, Perceive Biotherapeutics – Series B, Ellodi Pharmaceuticals – Series B, Tourmaline Bio – Series A, Jaanuu – Series B, Waterloo Sparkling Water – Series D, Bandier – Series E, ConnectRN – Series F
  • Mergers and Acquisitions:
    • Quidel in its acquisition of Ortho Clinical Diagnostics
    • Glassdoor in its sale to Recruit Holdings
    • BPGBio in its investment in Berg, LLC
    • California Water Service Group in Proposed Acquisition of SJW Group
    • Novus Therapeutics in merger transaction with Tokai Pharmaceuticals
    • Rocket Pharmaceuticals in merger transaction with Inotek

Melanie received her J.D. from the University of Michigan Law School in 2016, where she was the Managing Editor of the Michigan Business & Entrepreneurial Law Review. She earned her B.A., magna cum laude, in Communications, Legal Institutions, Economics and Government, with a minor in French, from American University in 2013.

Melanie is admitted to practice law in the State of California.

EDUCATION

University of Michigan - 2016 Juris Doctor

American University - Washington D.C. - 2013 Bachelor of Arts

ADMISSIONS

California Bar

RECENT PUBLICATIONS

Webcasts - July 19, 2023 | Webcast: Recent Developments – ATM Programs and Rights Offerings
Firm News - July 18, 2023 | Gibson Dunn Represents Apogee Therapeutics, Inc. in Upsized Initial Public Offering
Webcasts - July 11, 2023 | Webcast: Stock Buybacks: What You Need to Know (and Disclose) Following Adoption of the SEC’s New Rules
Webcasts - January 12, 2023 | Webcasts: Gibson Dunn’s Annual California MCLE Marathon – 2023
Client Alert - October 1, 2019 | Everyone Jump In! All Issuers Will Be Allowed to “Test-the-Waters”
Client Alert - July 12, 2018 | Shareholder Proposal Developments During the 2018 Proxy Season
Client Alert - November 21, 2016 | California Supreme Court Fall 2016 Round-Up
Client Alert - November 15, 2016 | The Trump Presidency: Selected Initial Observations and Considerations
  • Sitemap
  • Client Extranet
  • Terms of Use and Legal Notices
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2023 Gibson, Dunn & Crutcher LLP.  All rights reserved.  For contact and other information, please visit us at gibsondunn.com.
Top
Gibson Dunn uses cookies which are essential for our website to function. With your consent, we and third parties may also use non-essential cookies to collect information about your browsing activities, and improve the content, functionality and performance of our website. By clicking “Accept All”, you consent to the use of all cookies on our website as set out in our Cookie Notice. You can reject all non-essential cookies by clicking “Reject All”. Choose "Manage Cookies" to view and customize your cookie settings.
Manage CookiesACCEPT ALLREJECT ALL
Manage consent

Your Privacy Choices / Cookies

This website uses cookies – small text files stored on your device, when you visit a website - including third party cookies to collect information about your browsing activities and improve the content, functionality and performance of our website. Out of these cookies, the cookies that are categorized as Necessary Cookies are stored on your browser as they are essential for the operation of the website. You may accept all cookies, or reject all cookies other than Necessary Cookies.  If you visit us from a different device or browser, or clear cookies, then you may need to return to this screen to re-select your preferences.   Note that rejecting some of these cookies may have an effect on your browsing experience. Please note that if you do not make a selection below, only necessary cookies will be set.

You can learn more about our processing of your personal data by visiting our Privacy Policy.
Necessary
Always Enabled
Necessary cookies are essential for our website to function and cannot be switched off in our systems. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. Without these cookies, our website will not operate properly.   Cookie Details
Analytics
These cookies are used to collect information on how you use our website, including information about the pages you visited, how long you visited and if you experienced any errors. We use this information to help us improve the quality of our website and monitor the level of activity on our website. They may be set by third parties whose services have been added to our pages. Cookie Details
Save & Accept